A Clinical Evaluation Report (CER) is one of the most critical and heavily scrutinized regulatory documents in the medical device lifecycle. It provides documented evidence that a medical device is clinically safe, performs as intended, and delivers a favorable benefit-risk profile for patients and users.

With the introduction of the EU Medical Device Regulation (EU MDR 2017/745), the role of the Clinical Evaluation Report has evolved dramatically. CERs are no longer static, submission-only documents. Instead, they are now living clinical evidence files that must be actively maintained and updated throughout the entire product lifecycle.

For manufacturers, notified bodies, and regulatory authorities, a robust CER is essential to:

• Obtain and maintain CE marking
• Demonstrate compliance with General Safety and Performance Requirements (GSPRs)
• Support post-market surveillance (PMS) and PMCF
• Withstand increasing regulatory scrutiny and audits
• Protect patient safety and clinical outcomes

This comprehensive guide explains the definition, regulatory foundation, structure, best practices, and emerging trends shaping Clinical Evaluation Reports today.

What Is a Clinical Evaluation Report?

A Clinical Evaluation Report is a formal, systematic, and documented assessment of clinical data related to a medical device. Its primary objective is to confirm that the device:

• Achieves its intended purpose
• Is safe for patients and users
• Performs consistently under normal conditions of use
• Demonstrates a positive benefit-risk ratio
• Aligns with the current state of the art (SOTA)

Clinical data included in a CER may come from:

• Pre-market and post-market clinical investigations
• Published scientific and clinical literature
• Post-market surveillance data
• Post-Market Clinical Follow-Up (PMCF)
• Real-world evidence (RWE)

Under EU MDR, clinical evaluation is a continuous process, not a one-time activity.

Regulatory Importance of the Clinical Evaluation Report

Why CERs Are Heavily Scrutinized

Notified bodies consistently identify CER-related non-conformities as one of the leading causes of:

• Certification delays
• Additional clinical evidence requests
• Suspended or withdrawn CE certificates

Common regulatory concerns include:

• Insufficient clinical data for the intended use
• Weak literature appraisal methodology
• Unsupported equivalence claims
• Poor linkage between CER, PMS, and risk management
• Outdated or incomplete clinical conclusions

A well-prepared Clinical Evaluation Report directly reduces regulatory risk and accelerates market access.

Regulatory Framework Governing Clinical Evaluation Reports

EU MDR 2017/745 Requirements

Clinical evaluation requirements are primarily defined in:

• Article 61 – Clinical Evaluation
• Annex I – General Safety and Performance Requirements
• Annex XIV – Clinical Evaluation and PMCF

Key MDR expectations include:

• Use of qualified clinical evaluators
• Methodologically sound literature searches
• Objective appraisal and analysis of clinical data
• Justification of clinical claims
• Regular CER updates using PMS and PMCF data

Although MEDDEV 2.7/1 Rev. 4 is no longer legally binding, it remains widely used as a best-practice guidance document.

Clinical Evaluation Report Lifecycle Approach

Modern CERs follow a lifecycle-based approach, meaning they must be:

• Created during device development
• Updated after certification
• Reviewed periodically
• Revised when new clinical, PMS, or PMCF data becomes available

Any of the following can trigger a CER update:

• Design changes
• Expanded indications
• New clinical risks
• Serious incidents or trends
• Regulatory feedback

Standard Structure of a Clinical Evaluation Report

1. Executive Summary

A concise overview of:

• Device description
• Intended purpose
• Clinical evidence sources
• Overall clinical conclusions

2. Device Description and Intended Purpose

Includes:

• Device classification
• Intended use, indications, and contraindications
• Target patient population
• Principle of operation
• Accessories and variants

Clear alignment between intended purpose and clinical evidence is critical.

3. Scope of Clinical Evaluation

Defines:

• Regulatory pathway
• Clinical claims to be supported
• Applicable standards and guidance
• Evaluation objectives and limitations

4. Identification of Clinical Data

Documents:

• Literature search strategy
• Databases used (PubMed, Embase, Cochrane, etc.)
• Search terms and timeframes
• Inclusion and exclusion criteria

Transparency in search methodology is a key audit focus.

5. Appraisal of Clinical Data

Evaluates:

• Scientific validity
• Methodological quality
• Bias and limitations
• Relevance to the device and intended use

Poor appraisal methodology is one of the most common CER deficiencies.

6. Analysis of Clinical Data

Analyzes:

• Safety outcomes and adverse events
• Clinical performance endpoints
• Comparison to SOTA
• Consistency across data sources

7. Benefit-Risk Assessment

Demonstrates:

• Identified clinical benefits
• Known and foreseeable risks
• Risk mitigation measures
• Overall benefit-risk justification

8. Clinical Conclusions

Confirms whether:

• Clinical evidence is sufficient
• GSPRs are met
• PMCF is required or justified
• Claims are clinically supported

State of the Art (SOTA) in Clinical Evaluation Reports

Defining State of the Art is a mandatory MDR requirement. SOTA represents:

• Current clinical practices
• Existing alternative therapies or devices
• Accepted safety and performance benchmarks

The CER must show that the device:

• Performs at least as well as available alternatives
• Does not introduce unacceptable new risks
• Remains clinically relevant over time

Equivalence in Clinical Evaluation Reports

Challenges Under EU MDR

Equivalence claims must be justified across:

• Clinical equivalence
• Technical equivalence
• Biological equivalence

Manufacturers must have:

• Sufficient access to technical documentation
• Strong scientific justification
• Clear rationale for relevance

Due to stricter MDR expectations, reliance on equivalence alone has become increasingly difficult.

Role of PMCF in Clinical Evaluation Reports

Post-Market Clinical Follow-Up

PMCF is an essential component of ongoing clinical evaluation. Under MDR:

• PMCF is expected for most devices
• Justification is required if PMCF is not conducted
• PMCF outputs must feed directly into CER updates

PMCF activities may include:

• Post-market clinical studies
• Registries
• Surveys and feedback
• Real-world performance analysis

Trending Topic: CERs for Software and AI Medical Devices

For Software as a Medical Device (SaMD) and AI-based devices, CERs must address:

• Clinical validation of algorithms
• Dataset relevance and representativeness
• Bias and performance drift
• Usability and cybersecurity risks

Regulators increasingly expect real-world performance monitoring for adaptive AI systems.

Trending Topic: Real-World Evidence (RWE) in CERs

Real-world evidence is gaining acceptance when:

• Clinical trials are impractical
• Long-term safety data is needed
• PMCF supports ongoing performance claims

RWE must still meet standards for data quality, relevance, and traceability.

Common CER Deficiencies Identified by Notified Bodies

Frequent findings include:

• Incomplete literature searches
• Unsupported clinical claims
• Weak benefit-risk analysis
• Missing linkage to risk management
• Infrequent CER updates

Proactively addressing these issues significantly improves approval success.

Best Practices for High-Quality Clinical Evaluation Reports

From real regulatory experience:

• Start clinical evaluation early
• Use qualified clinical experts
• Maintain traceability to GSPRs
• Align CER, PMS, PMCF, and risk files
• Treat the CER as a strategic document, not an administrative task

Conclusion

The Clinical Evaluation Report is a cornerstone of medical device regulatory compliance. In the EU MDR era, CERs must be robust, transparent, continuously updated, and scientifically sound.

Manufacturers that invest in high-quality clinical evaluation not only achieve regulatory approval faster but also strengthen patient trust, clinical credibility, and long-term market success.